translation agency

PR Newswire
ADVR Names Dr. Mark H. Kaplan to Scientific Advisory Board: Noted AIDS Physician and Research Scientist Joins Experts In Cancer, Immunology and Microbiology

May 15, 2002
YONKERS, N.Y., May 15 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that Mark H. Kaplan, MD, has joined the Company's Scientific Advisory Board. Dr. Kaplan brings specialized expertise in AIDS treatment and research, including the study of new therapeutic agents, to the Scientific Advisory Board.

Dr. Kaplan is the Jane and Dayton Brown Professor of Clinical Medicine at The New York University School of Medicine and has been Director of The Center for AIDS Research and Treatment at The North Shore University Hospital since 1994. Dr. Kaplan, a prominent specialist in infectious diseases who now devotes his attention to problems of AIDS, was previously Chief of Infectious Diseases at The North Shore University Hospital from 1980 through 1994. He also had served on the adjunct staff and was guest investigator at Rockefeller University from 1978 through 1984.

"We are aggressively pursuing the possible use of Product R in the treatment of HIV infection and AIDS, and we are awaiting approval to begin clinical studies of Product R in AIDS related wasting (cachexia) and the possible salvage effects of Product R in these patients. Dr. Kaplan's expertise will be important in helping to define the promising role of Product R in the treatment of AIDS," stated Shalom Z. Hirschman, MD, Chief Executive Officer and President of Advanced Viral Research Corp. "Dr. Kaplan has conducted many clinical trials in patients with AIDS, including studying the therapeutic potential of such drugs such as Viracept and new drug combinations in patients with AIDS, and we look forward to his counsel in the development of our innovative drug, Product R."

"There is a definite need for new types of therapies to alleviate the sufferings of patients with AIDS. I am eager to work with the other members of the Scientific Advisory Board and the scientific staff of Advanced Viral Research Corp. to help establish the role of Product R in the treatment of patients with AIDS," said Dr. Kaplan. "Product R represents a new type of potential therapy for patients with AIDS and should be subjected to rigorous clinical trials to decipher its role in the treatment of patients with HIV infection and AIDS. I look forward to the exciting prospect of helping to advance these scientific investigations."

Dr. Kaplan joins fellow Scientific Advisory Board members Dr. Howard A. Young, a world-renowned microbiologist and immunologist; Dr. George Canellos (Harvard Medical School and Dana Farber Cancer Institute); Dr. Michael Harris (Tomorrows Children's Institute for Cancer and Blood Disorders and UMDNJ-New Jersey Medical School); Dr. James D'Olimpio (North Shore University Hospital and New York University School of Medicine); and Ms. Carol Armenti (Center for Cervical Health). The Company formed the Scientific Advisory Board in January to bring broad-ranging scientific expertise to the Company's efforts to develop its flagship drug, Product R.

Product R is being investigated as a non-toxic peptide-nucleic acid-type immunomodulator that appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, Product R has been termed a "switch type" immunomodulator. Product R is also being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs, including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of cancers.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of Product R or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Contact Information:

Mayr Communications, Inc.

877-777-6010

mayrcomm@att.net



www.aegis.org